Loading…
Immunome, Inc. is projected to rise to $29.78 by 2027, a +29% move from its current price of $23.08. IMNM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $22.60 | $23.09 | $23.60 | +0.05% |
| Aug 2 | $22.41 | $23.10 | $23.82 | +0.10% |
| Aug 3 | $22.26 | $23.12 | $24.00 | +0.16% |
| Aug 4 | $22.15 | $23.13 | $24.15 | +0.21% |
| Aug 5 | $22.04 | $23.14 | $24.29 | +0.26% |
| Aug 6 | $21.95 | $23.15 | $24.41 | +0.31% |
| Aug 7 | $21.87 | $23.16 | $24.53 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.87 | $23.16 | $24.53 | +0.36% |
| Week 2 | $21.44 | $23.25 | $25.21 | +0.73% |
| Week 3 | $21.13 | $23.33 | $25.77 | +1.09% |
| Week 4 | $20.88 | $23.42 | $26.26 | +1.46% |
| Week 5 | $20.67 | $23.50 | $26.72 | +1.83% |
| Week 6 | $20.49 | $23.59 | $27.15 | +2.20% |
| Week 7 | $20.34 | $23.67 | $27.55 | +2.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunome, Inc. is a biotechnology company that engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical assets comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. (IMNM) is a healthcare asset with a current price of $23.61 and a market cap of $2.67B. It ranks 1806 by market cap. The current price and market position place Immunome among healthcare equities with a modest ranking given its market size.
A major floor 30.1% below — a decisive break under it would weaken the trend.
The nearest floor, 19.7% below — buyers have tended to step in here.
The nearest ceiling, 5.7% above — a clean break opens room to run.
A major ceiling 20.7% above — clearing it would confirm fresh momentum.
Key IMNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.84 | Buy | $22.92 | Buy |
| MA 10 | $22.63 | Buy | $22.77 | Buy |
| MA 20 | $23.01 | Buy | $22.46 | Buy |
| MA 50 | $21.18 | Buy | $21.87 | Buy |
| MA 100 | $21.59 | Buy | $21.46 | Buy |
| MA 200 | $20.92 | Buy | $19.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.87 | Neutral |
| Stoch RSI (14) | 83.46 | Sell |
| CCI (20) | 7.65 | Neutral |
| Williams %R (14) | -11.57 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | 2.17 | Buy |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 88.43 | Sell |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 1.32 | Buy |
| Ultimate (7,14,28) | 55.36 | Neutral |
| Momentum (10) | 0.88 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 23.20 | Sell |
| ADX (14) | 17.04 | Neutral |
| ATR (14) | 0.41 | Info |
The 30-day picture is bullish, with sentiment labeled as BULLISH and RSI14 at 70. The stock’s technical posture is supported by the SMA50 at $21.07 and the SMA200 at $19.83. Near-term support sits at $17.91 and near-term resistance at $23.61. The 30-day price range spans from $19.33 to $28.84.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.91 | $23.08 | $29.82 | 0% | Neutral | |
| $24.20 | $29.78 | $38.47 | +29% | Bullish | |
| $29.43 | $37.04 | $49.33 | +60% | Bullish | |
| $34.27 | $43.90 | $59.90 | +90% | Bullish | |
| $38.16 | $49.66 | $69.15 | +115% | Bullish | |
| $38.11 | $50.31 | $71.31 | +118% | Bullish | |
| $42.64 | $57.05 | $82.16 | +147% | Bullish | |
| $49.73 | $67.36 | $98.42 | +192% | Bullish | |
| $55.50 | $76.06 | $112.62 | +230% | Bullish | |
| $63.93 | $88.59 | $132.82 | +284% | Bullish | |
| $93.14 | $135.70 | $214.37 | +488% | Bullish | |
| $157.71 | $249.91 | $426.39 | +983% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $17.91 | $23.08 | $26.88 | +0.00% |
| August 2026 | $20.07 | $23.45 | $27.97 | +1.60% |
| September 2026 | $20.57 | $24.20 | $29.17 | +3.18% |
| October 2026 | $20.37 | $24.09 | $29.28 | -0.44% |
| November 2026 | $19.98 | $23.73 | $29.04 | -1.51% |
| December 2026 | $20.30 | $24.21 | $29.82 | +2.03% |
Click any year to see its month-by-month IMNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMNM could reach as high as $29.82, with a base case around $23.08 and support toward $17.91 — roughly 0% from $23.08. Price action looks broadly range-bound.
Expect IMNM to range from $24.20 to $38.47 through 2027. The $29.78 average target implies a +29% move from current prices. That is up +29% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IMNM price prediction for 2028 points to an average of $37.04 (low $29.43, high $49.33) — a potential gain of +60% on today's $23.08. Momentum favours further upside here.
In 2029, IMNM is projected to trade between $34.27 and $59.90, averaging $43.90 — a potential gain of +90% from today's $23.08. That is up +19% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Immunome, Inc.'s 2030 outlook centres on $49.66, within a $38.16 to $69.15 range. That is up +13% on the projected 2029 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2031, IMNM could reach as high as $71.31, with a base case around $50.31 and support toward $38.11 — roughly +118% from $23.08. Buyers look set to stay in control over this stretch.
Expect IMNM to range from $42.64 to $82.16 through 2032. The $57.05 average target implies a +147% move from current prices. That is up +13% on the projected 2031 average. Momentum favours further upside here.
The IMNM price prediction for 2033 points to an average of $67.36 (low $49.73, high $98.42) — a potential gain of +192% on today's $23.08. Buyers look set to stay in control over this stretch.
In 2034, IMNM is projected to trade between $55.50 and $112.62, averaging $76.06 — a potential gain of +230% from today's $23.08. That is up +13% on the projected 2033 average. Momentum favours further upside here.
Immunome, Inc.'s 2035 outlook centres on $88.59, within a $63.93 to $132.82 range. That is up +16% on the projected 2034 average. That marks a +284% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IMNM could reach as high as $214.37, with a base case around $135.70 and support toward $93.14 — roughly +488% from $23.08. Momentum favours further upside here.
Expect IMNM to range from $157.71 to $426.39 through 2050. The $249.91 average target implies a +983% move from current prices. That is up +84% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMNM today (≈ 43.327556 IMNM) could be worth
$10,828.2
+$9,828.2 (+983%) by 2050 · US Dollar
Based on the average projected IMNM price of $249.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMNMwould be worth at today's price.
$1,000 invested in IMNM on Jul 30, 2025 (≈ 93.023256 IMNM) would be worth
$2,146.98
+$1,146.98 (+114.7%) today · 2.15× · US Dollar
Based on a IMNM entry price of $10.75 vs. today's $23.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $22.01 | $1,048.61 | +4.9% |
| 1 month ago | $21.19 | $1,089.19 | +8.9% |
| 3 months ago | $22.73 | $1,015.4 | +1.5% |
| 6 months ago | $24.62 | $937.45 | -6.3% |
| 1 year ago | $10.75 | $2,146.98 | +114.7% |
| All time (5.0y) ago | $15.77 | $1,463.54 | +46.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMNM forecast.
Our base-case forecast reaches $46.00 around 2030.
Implied market cap at $46.00: $5.21B
The multi-year forecast shows a strong upside trend with rising averages and notable ROIs. For 2026, the average price is $23.61 with a 0% ROI and a neutral sentiment. In 2027, the average is $30.71 with a 30.1% ROI and bullish sentiment.
In 2028, the average is $41.72 with a 76.7% ROI and bullish sentiment. In 2029, the average is $48.45 with a 105.2% ROI and bullish sentiment. By 2030, the average is $52.36 with a 121.8% ROI and bullish sentiment.
The trajectory continues through 2031 with an average of $54.30 (130% ROI), 2032 at $61.43 (160.2% ROI), 2033 at $71.92 (204.6% ROI), 2034 at $84.67 (258.6% ROI), and 2035 at $99.84 (322.9% ROI). By 2040 the average reaches $155.33 with a 557.9% ROI, and by 2050 the average is $268.33 with a 1036.5% ROI, all with bullish sentiment. These figures reflect estimates of future pricing and are not guarantees; outcomes depend on market and clinical development factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $52.36 with a min of $38.03 and a max of $77.92, and a ROI of 121.8% with bullish sentiment.
The forecast shows meaningful upside through 2050, with the average price rising to $268.33 and a ROI of 1036.5% by 2050, along with bullish sentiment in later years. These are estimates and not guarantees.
Yes, the 2035 forecast lists an average of $99.84 and a max of $163.44 (bullish). The max in 2035 exceeds 100, and later years show even higher maxima (e.g., 2040 max $271.73 and 2050 max $516.82).
The sentiment is BULLISH with RSI14 at 70. Key levels are SMA50 at $21.07 and SMA200 at $19.83, with near-term support at $17.91 and resistance at $23.61. The 30-day price range is $19.33 to $28.84.
Current price is $23.61 and market cap is $2.67B. The asset ranks 1806.
Immunome, Inc. Community Discussion
0Share your Immunome, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.